| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.014 | 0.6 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |